Physician profile
Adrian A Bunta
NPI 1043542061
$58,906.60
in general payments reported to CMS, 2019-2025
66 companies · $18K in 2025
The $18K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,033 · 2022: $4,224 · 2023: $16K · 2024: $19K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Food and Beverage: $18K · Travel and Lodging: $3,323 · Education: $473 · Consulting Fee: $330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,879.50 |
| Food and Beverage | $17,645.75 |
| Travel and Lodging | $3,322.56 |
| Education | $472.56 |
| Consulting Fee | $330.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $35,415.18 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $3,309.82 | 2023-2025 | Rexulti, Nuedexta |
| Abbvie INC. | $2,819.53 | 2021-2025 | |
| Ucb, INC. | $1,874.09 | 2022-2025 | Briviact, Rystiggo, Fintepla |
| Lilly USA, LLC | $1,044.24 | 2022-2025 | Emgality, Reyvow, Amyvid |
| Amneal Pharmaceuticals LLC | $936.32 | 2022-2025 | Rytary, Crexont, Lyvispah |
| Biohaven Pharmaceuticals, INC. | $934.24 | 2021 | |
| Novartis Pharmaceuticals Corporation | $854.66 | 2022-2025 | |
| Acadia Pharmaceuticals INC | $764.36 | 2022-2025 | Nuplazid |
| Biogen, INC. | $739.57 | 2023-2025 | Vumerity, Tysabri, Spinraza |
| Alexion Pharmaceuticals, INC. | $707.81 | 2022-2024 | Ultomiris |
| Sk Life Science, INC. | $686.44 | 2022-2025 | Xcopri |
| Eisai INC. | $680.66 | 2021-2025 | |
| Argenx US, INC. | $643.32 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Emd Serono, INC. | $628.03 | 2023-2025 | Mavenclad, Mavenclad |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrian Bunta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.